Gilead and Merck provide HIV data; Dimension Capital announces $800M fund

Phase 3Neutral

AI Analysis

Summary

Gilead and Merck announced they will present detailed Phase 3 trial results for a once-weekly oral HIV treatment regimen at AIDS 2026. Separately, Dimension Capital announced an $800M fund.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Phase 3 trial results for once-weekly oral HIV treatment regimen to be presented at AIDS 2026

Importance:6/10

Sentiment:

0.20

HIVPhase 3GileadMerckoral treatmentonce-weeklyAIDS 2026 conference

Related Companies

$GILD $MRK

Read the original article

Published by Endpoints News on July 21, 2026 3:30 PM

Read Original